



CELLULAR AND TISSUE ENGINEERING SYMPOSIUM

Advancing the Next Generation of Biotech Leaders

David Johnson, Ph.D., CEO and Founder, GigaMune

"The Journey from a Ph.D. in Sea Squirt Genetics to Founding Three Biotechs"

Bio:

David Johnson is an inventor, entrepreneur, and expert in genomics with a track record of bringing new medical technologies to the clinic and the market. He is founder and CEO of GigaMune, which is developing novel technology for in vivo targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) to treat serious diseases such as cancer and autoimmune diseases. Their vision is to bring gene therapy into mainstream medicine through in vivo delivery of any gene to any cell in any tissue location. The initial goal is to challenge conventional ex vivo cell therapy manufacturing by reducing costs and improving outcomes. Previously, Johnson brought GigaGen's massively diverse recombinant polyclonal antibody drugs from concept to clinic. He led negotiation and sale of the company to Grifols for a valuation of \$142.9 million (with potential for further product related earnout) in March 2021. He was also among the founding members and COO of Natera (NASDAQ: NTRA). Prior to Natera, he was the ENCODE Project Director at the Stanford Human Genome Center. David Johnson holds a B.S. in Biology from Duke University, a Ph.D. in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.